The database attempts to capture information on molecular characteristics of the diagnosed cancers but many patients have missing data; for GBM, MGMT methylation status, an important prognostic factor 32, was only available for 2.1% of our patient population (N = 98), and 1p19q status was only available for 0.9%. This evidence concerns the gene MGMT and glioblastoma.